New Trial: Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Trial Overview

NCT ID: NCT06067737 Phase: PHASE2 Enrollment Target: 90 Status: Recruiting

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone buprenorphine induction before. Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with outpatient buprenorphine maintenance, quality of life, and mood.

Why This Matters

[Draft — editorial context needed]

Source

• View full trial on ClinicalTrials.gov